tetano
Editor, Senior Moderator
Infect Dis Ther
. 2024 May 27.
doi: 10.1007/s40121-024-00987-2. Online ahead of print. Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
Sushma Kavikondala[SUP] 1 [/SUP], Katrin Haeussler[SUP] 2 [/SUP], Xuan Wang[SUP] 3 [/SUP], Anne Spellman[SUP] 4 [/SUP], Mary T Bausch-Jurken[SUP] 5 [/SUP], Pawana Sharma[SUP] 6 [/SUP], Mohammadreza Amiri[SUP] 1 [/SUP], Anna Krivelyova[SUP] 6 [/SUP], Sonam Vats[SUP] 7 [/SUP], Maria Nassim[SUP] 8 [/SUP], Nitendra Kumar[SUP] 7 [/SUP], Nicolas Van de Velde[SUP] 9 [/SUP]
Affiliations
Introduction: Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose coronavirus disease 2019 (COVID-19) vaccines may offer increased immunogenicity.
Methods: A pairwise meta-analysis of 98 studies reporting comparisons of mRNA-1273 (50 or 100 mcg/dose) and BNT162b2 (30 mcg/dose) in IC adults was performed. Outcomes were seroconversion, total and neutralizing antibody titers, and cellular immune responses.
Results: mRNA-1273 was associated with a significantly higher seroconversion likelihood [relative risk, 1.11 (95% CI, 1.08, 1.14); P < 0.0001; I[SUP]2[/SUP] = 66.8%] and higher total antibody titers [relative increase, 50.45% (95% CI, 34.63%, 66.28%); P < 0.0001; I[SUP]2[/SUP] = 89.5%] versus BNT162b2. mRNA-1273 elicited higher but statistically nonsignificant relative increases in neutralizing antibody titers and cellular immune responses versus BNT162b2.
Conclusion: Higher-dose mRNA-1273 had increased immunogenicity versus BNT162b2 in IC patients.
Keywords: BNT162b2; COVID-19; Cellular immunity; Immunocompromised; Neutralizing antibody; Seroconversion; Severe acute respiratory syndrome coronavirus–2; Total antibody; mRNA vaccine; mRNA-1273.
. 2024 May 27.
doi: 10.1007/s40121-024-00987-2. Online ahead of print. Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE
Sushma Kavikondala[SUP] 1 [/SUP], Katrin Haeussler[SUP] 2 [/SUP], Xuan Wang[SUP] 3 [/SUP], Anne Spellman[SUP] 4 [/SUP], Mary T Bausch-Jurken[SUP] 5 [/SUP], Pawana Sharma[SUP] 6 [/SUP], Mohammadreza Amiri[SUP] 1 [/SUP], Anna Krivelyova[SUP] 6 [/SUP], Sonam Vats[SUP] 7 [/SUP], Maria Nassim[SUP] 8 [/SUP], Nitendra Kumar[SUP] 7 [/SUP], Nicolas Van de Velde[SUP] 9 [/SUP]
Affiliations
- PMID: 38802704
- DOI: 10.1007/s40121-024-00987-2
Introduction: Immunocompromised (IC) patients mount poor immune responses to vaccination. Higher-dose coronavirus disease 2019 (COVID-19) vaccines may offer increased immunogenicity.
Methods: A pairwise meta-analysis of 98 studies reporting comparisons of mRNA-1273 (50 or 100 mcg/dose) and BNT162b2 (30 mcg/dose) in IC adults was performed. Outcomes were seroconversion, total and neutralizing antibody titers, and cellular immune responses.
Results: mRNA-1273 was associated with a significantly higher seroconversion likelihood [relative risk, 1.11 (95% CI, 1.08, 1.14); P < 0.0001; I[SUP]2[/SUP] = 66.8%] and higher total antibody titers [relative increase, 50.45% (95% CI, 34.63%, 66.28%); P < 0.0001; I[SUP]2[/SUP] = 89.5%] versus BNT162b2. mRNA-1273 elicited higher but statistically nonsignificant relative increases in neutralizing antibody titers and cellular immune responses versus BNT162b2.
Conclusion: Higher-dose mRNA-1273 had increased immunogenicity versus BNT162b2 in IC patients.
Keywords: BNT162b2; COVID-19; Cellular immunity; Immunocompromised; Neutralizing antibody; Seroconversion; Severe acute respiratory syndrome coronavirus–2; Total antibody; mRNA vaccine; mRNA-1273.